Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Abstract Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide
and a major economic burden. The prevalence of T2DM is rising, suggesting more effective …

Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in
significant physical and psychological detriment to patients. As of 2019, 463 million people …

Type 2 diabetes mellitus (T2DM) is one of the greatest health crises of our time and its
prevalence is projected to increase by> 50% globally by 2045. Currently, 10 classes of …

Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

Type 2 diabetes mellitus (T2 DM) is caused by insulin resistance and characterized by
progressive pancreatic β‐cell dysfunction. This articles reviews the application and …

Sulphonylureas (SUs) and biguanides (metformin) are the current mainstays in the treatment
of type 2 diabetes (T2DM) and represent the most commonly used oral hypoglycaemic …

BACKGROUND Diabetes is a deadly and costly disease. The number of adults in the United
States with newly diagnosed diabetes has nearly tripled from 1980 to 2011. At the current …

Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global
cartographic picture of diabetes by the International Diabetes Federation (http://www …

To achieve good metabolic control in diabetes and keep long term, a combination of
changes in lifestyle and pharmacological treatment is necessary. Achieving near-normal …